FIGURE 1.

Extract of some of the most important clinical topics discussed at the workshop. Some of the most relevant clinical aspects and unmet needs were addressed by Clifford Kashtan (clinician's view) and Sharon Lagas (patient's view): (i) the value of a new, easier classification of the AS to enable earlier diagnosis and treatment; (ii) the role of biomarkers, international registries and open access to data; (iii) possible risks (and pricing) of new therapies; (iv) combined effort of researchers, clinicians, patients and the pharmaceutical/biotech industry to find better therapies; and (v) the role of patient organizations. XLAS, X-linked Alport syndrome; ADAS, autosomal dominant Alport syndrome; TBMN, thin basement membrane nephropathy; ARAS, autosomal recessive Alport syndrome.